Pharma Marketing Network

Twitter just announced a complex, confusing, and developer-alienating system that restricts their once-open, always cherished but now apparently taken for granted API. The new rules change the playing field for third party developers, establish caps on number of users, and shift guidelines to requirements across four categories of businesses. Will these new API restrictions curtail growth of health-related third-party apps and, if so, will that ultimately be

I just received this comment via my "Contact Us" form: "John, while the information you post online is informative and I am glad someone is...

The "DDR on DTC" column in the August 2012 issue of MM&M magazine ripped into a print ad that showed a woman migraine sufferer...

Welcome to Volume 10, Issue #13 (23 AUGUST 2011) of Pharma Marketing News.

According to Drugs.com, Lipitor U.S. sales in Q2 of 2012 were only 30% of what they were in Q2 2011 ($579 million vs....

John Pugh, Director of Digital for Boehringer Ingelheim GmbH (BI), announced that BI will release a BETA version of the FaceBook game SYRUM at...

Exploring the new commercial model based on 'informed,' data-driven relationship marketing and technology. A conversation with Bob Harrell, VP of Marketing at Appature. Bob discusses the transformation currently underway in the pharma commercial model, as well as his company's

An article in yesterday's NYT focused on what I call "Prescription Grade Smartphone Medical Apps." The article said the idea of such apps "excites...

Michael Ritchie, Postdoctoral Fellow at Pfizer, recently posted to the Think Science Blog that he was NOT surprised that the American public "lost significant...

"Few people in pharma or the investment community were surprised at bapineuzumab's failure, as most odds makers put its chances for success at approximately...